AN2 Therapeutics
Filed with the SEC on · accession 0001193125-26-452664
ANTX filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +0.0% by the first close after the filing.
AN2 Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results including R&D and G&A expenses, share-based compensation, and ATM equity sales activity.
Close before
$4.00
Nov 6, 2026
First close after
+0.00%
$4.00
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ANTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ANTX?
Click hereANTX filed a 10-Q (SEC filing). AN2 Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results including R&D and G&A expenses, share-based compensation, and ATM equity sales activity.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
ANTX closed at $4.00 before the filing and $4.00 on Nov 9, 2026 (+0.00%).
Get alerts when ANTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days